vs
Side-by-side financial comparison of Inventiva S.A. (IVA) and Processa Pharmaceuticals, Inc. (PCSA). Click either name above to swap in a different company.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for patients with high unmet medical needs. Its core product pipeline targets rare diseases, gastrointestinal disorders, and dermatological conditions, with primary operational focus on the North American and European healthcare markets.
IVA vs PCSA — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2023
| Metric | | |
|---|---|---|
| Revenue | $5.1K | $0 |
| Net Profit | $-49.0M | $-2.1M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | -961352.9% | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | 65.4% |
| EPS (diluted) | — | $-1.54 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 24 | $5.1K | — | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 | ||
| Q1 23 | — | $0 | ||
| Q4 22 | — | $0 | ||
| Q3 22 | — | $0 | ||
| Q2 22 | — | $0 | ||
| Q1 22 | — | $0 |
| Q2 24 | $-49.0M | — | ||
| Q3 23 | — | $-2.1M | ||
| Q2 23 | — | $-2.6M | ||
| Q1 23 | — | $-4.0M | ||
| Q4 22 | — | $-13.0M | ||
| Q3 22 | — | $-6.0M | ||
| Q2 22 | — | $-5.2M | ||
| Q1 22 | — | $-3.2M |
| Q2 24 | -961352.9% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q2 24 | — | — | ||
| Q3 23 | — | $-1.54 | ||
| Q2 23 | — | $-1.94 | ||
| Q1 23 | — | $-3.53 | ||
| Q4 22 | — | — | ||
| Q3 22 | — | $-0.37 | ||
| Q2 22 | — | $-0.32 | ||
| Q1 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.0M | $6.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-85.4M | $7.2M |
| Total Assets | $42.6M | $8.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | $11.0M | — | ||
| Q3 23 | — | $6.9M | ||
| Q2 23 | — | $8.7M | ||
| Q1 23 | — | $10.7M | ||
| Q4 22 | — | $6.5M | ||
| Q3 22 | — | $9.1M | ||
| Q2 22 | — | $12.1M | ||
| Q1 22 | — | $14.4M |
| Q2 24 | $-85.4M | — | ||
| Q3 23 | — | $7.2M | ||
| Q2 23 | — | $9.2M | ||
| Q1 23 | — | $10.1M | ||
| Q4 22 | — | $7.5M | ||
| Q3 22 | — | $17.2M | ||
| Q2 22 | — | $20.1M | ||
| Q1 22 | — | $23.2M |
| Q2 24 | $42.6M | — | ||
| Q3 23 | — | $8.1M | ||
| Q2 23 | — | $10.1M | ||
| Q1 23 | — | $12.4M | ||
| Q4 22 | — | $8.6M | ||
| Q3 22 | — | $18.6M | ||
| Q2 22 | — | $21.7M | ||
| Q1 22 | — | $24.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | — | — | ||
| Q3 23 | — | $-1.8M | ||
| Q2 23 | — | $-2.1M | ||
| Q1 23 | — | $-2.1M | ||
| Q4 22 | — | $-2.5M | ||
| Q3 22 | — | $-3.0M | ||
| Q2 22 | — | $-2.3M | ||
| Q1 22 | — | $-1.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
